CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
Pregabalin +1 moredrug
Likely dose
Pregabalin 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01117766
NCT01117766N/ACompleted
CompareCT.gov

A Randomized, Double Blind, Placebo Controlled, 2-Way Crossover Methodology Study Designed To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing (QST) In Patients With Neuropathic Pain Treated With Pregabalin Vs Placebo

Pfizer·interventional·Posted May 5, 2010·Updated Apr 23, 2019

In Brief

A clinical study evaluating Pregabalin and Placebo for Neuropathic Pain. Completed, enrolled 31 participants across 5 sites in 4 countries.

Detailed Summary

Conventional pain efficacy measures such as Visual Analogue Scores (VAS) are often unable to detect treatment efficacy in small-scale clinical trials. Combining conventional pain efficacy measures with quantitative sensory testing (QST) may provide more sensitive and informative outcome measures in clinical trials.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain
CountriesAustria, Belgium, France, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 5, 2010
Enrollment StartDec 1, 2006
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.2 years ago

Interventions

Pregabalindrug

Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients

Placebodrug

BID dosing for 28 days